OHSU Center for Evidence-based Policy Rhonda Anderson, RPh Director of Pharmacy EMPAA 2017 October 30, 2017
|
|
- Jeffery Rose
- 5 years ago
- Views:
Transcription
1 OHSU Center for Evidence-based Policy Rhonda Anderson, RPh Director of Pharmacy EMPAA 2017 October 30, 2017
2 Wedding Day Preparation
3 The Big Moment is Here
4 Mr. & Mrs. Anderson
5 Today s Presentation Center for Evidence-based Policy (CEbP): Overview of the Center CEbP Work with States State Medicaid Alternative Reimbursement and Purchasing Test for High Cost Drugs (SMART-D): Project Overview Initial Experience Working with States 5
6 Disclosure Declaration I have no actual or potential conflicts of interest to disclose in relation to this presentation. 6
7 Center for Evidence-based Policy: Overview of the Center and Our Work with States 7
8 Who We Are Center for Evidence-based Policy Established in 2003 Based at Oregon Health & Science University Applying data and evidence to public policy challenges Evidence review, data analysis, stakeholder engagement, policy development 35 people - MPH, PhD, MD, RPh Not academic publishing focused (or interested)
9 Who We Are Center for Evidence-based Policy Our work is driven by states, 90% in Medicaid We are not funded by industry or associations We have one foundation grant (LJAF) Worked with 25 states in the past two years We do not lobby We are nonpartisan
10 Center for Evidence-based Policy Center Mission: Addressing policy challenges with evidence and collaboration 10
11 Center for Evidence-based Policy Currently the Center works with 25 states: Multi state Collaborations Single state Evidence Assistance & Data Health Process Systems Engineering Others MED NY NH CO MPC DERP OR WA ACH SMART D WA Medical Cannabis (work in progress) P4P TX EiHP
12 Who We Are Our two largest programs: MED 20 states Research, evidence, policy for Medicaid (largely excluding pharmacy) DERP 14 states Research, evidence, comparative effectiveness for Medicaid pharmacy
13 Drug Effectiveness Review Project Self-governing collaboration of organizations that: Obtains and synthesizes global evidence on the comparative effectiveness, safety, and effects on subpopulations of drugs within classes. Supports policy makers in using evidence to inform policies for local decision making. Produces recently expanded evidence products to meet changing needs Refined focus in July 2012 Focus on high-impact, specialty drugs Proprietary beginning in July 2012 Expanded evidence products to meet changing needs
14 DERP Mission The Drug Effectiveness Review Project (DERP) is a trailblazing collaborative state Medicaid and public pharmacy programs DERP produces concise, comparative, evidence-based products that assist policymakers and other decision-makers grappling with difficult drug coverage decisions Collaborative founded in 2003 Under Gov. Kitzhaber s Administration Originally was 3 state collaboration that expanded to include up to 15 states Oregon Washington Idaho Was the building block for the Center for Evidence-based Policy
15 Participating States Washington Oregon Idaho Montana Colorado Texas Minnesota Wisconsin Missouri Tennessee North Carolina New York District of Columbia
16 16
17 State Situation and Needs New high-cost therapies are increasing State budgets are finite 49 states have balanced budget requirements States need better tools to provide access while managing costs. DERP SMART-D
18 State Medicaid Drug Spending Nationwide, state Medicaid drug spending grew at 14% between 2014 and 2015 States are feeling the pinch: Florida had to provide an additional payment to Medicaid managed care plans for covering hepatitis C drug costs in 2014 Missouri had to seek a midyear supplemental appropriation of $150m to address escalating drug costs in Medicaid in 2016 In 2016, Washington reported that it would cost $242m/year to provide drugs for high-risk hepatitis C patients and $1.0b/year if treatment were provided for all the state s Medicaid clients infected with hepatitis C Sources: National Health Expenditures, Statistics Data and Systems/Statistics Trends and Reports/ NationalHealthExpendData /index.html; FL & MO in SMART D Summary Report, 2016, d.org/wp content/uploads/2016/09/smart D Summary Report Final.pdf ; WA from news/health/lawsuit targets medicaid policy that limits spendy hep c drugs/ 18
19 Medicaid Pharmacy Program Dynamics State management tools are limited States are required to cover if a federal rebate agreement exists States cannot use closed formularies, although preferred drug lists are allowed; Prescription limits are regulated States can negotiate supplemental state rebates; kept confidential. States can use prior authorization criteria with the PDL but in the end, the states will have to pay regardless of efficacy 19
20 MDRP Dynamics Medicaid Best Price provisions do not necessarily get triggered by Medicaid Supplemental rebate negotiated by state Medicaid agencies will not trigger Best Price ; Best Price is a lever in commercial negotiations CPI penalty impact Incentive for manufacturers to set a high price upon entering MDRP because increases are limited to CPI CPI penalty can reduce price of brand name drug to Medicaid so it is less expensive than a new generic equivalent 20
21 Other Federal and State Requirements Other federal issues Prohibition against off-label promotion by manufacturers Anti-kickback statute Overlapping discounts with 340B prices, payer rebates, etc. Relevant state law Preferred drug list and prior authorization exclusions Any willing provider laws Regulation of MCOs and pharmacy benefit managers (PBMs) requiring transparency, etc. 21
22 State Medicaid Alternative Reimbursement and Purchasing Test for High Cost Drugs (SMART-D): Project Overview 22
23 SMART-D Project Goals CEbP has undertaken a three-year, three-phase pilot program funded by the Laura and John Arnold Foundation. The program has the following purposes: to strengthen the ability of Medicaid programs to manage prescription drugs through alternative payment methodologies, and to provide Medicaid leaders with opportunities to shape the national conversation on prescription drug innovation, access and affordability 23
24 Summary of Project Phases PHASE ONE: DISCOVER (FEBRUARY JULY 2016) Complete Situational Analysis: Alternative Purchasing Model Barriers and Opportunities PHASE TWO: DISSEMINATE (AUGUST 2016 APRIL 2017) Develop and Secure Implementation Plans for Alternative Purchasing Models PHASE THREE: IMPLEMENT (MAY 2017 APRIL 2018) Three to Five States Implement Alternative Purchasing Models (scope based on implementation plans) 24
25 Alternative Payment Models An APM is a contract between a payer and drug manufacturer that ties payment for a drug or drugs to an agreed-upon measure Our research has highlighted two pathways of APMs in Europe and the U.S.: Financial-based Health outcome-based 25
26 APMs Financial-based APMs Designed at either patient or population level Rely on financial caps or discounts to provide predictability and limit financial risk Financial targets tend to be easier to administer Health outcome-based APMs Payments tied to predetermined clinical outcomes or measurements Sometimes conditional coverage while data is collected regarding clinical effectiveness Can require significant data collection, but have potential to increase quality, value and efficiency of treatment 26
27 APMs 27
28 Medicaid Prescription Drug APMs: Putting the Pieces Together DRUGS IN THE PIPELINE APM S USED IN OTHER MARKETS/ COUNTRIES CURRENT MEDICAID PRESCRIPTION DRUG PRACTICES PRESCRIPTION DRUG ALTERNATIVE PAYMENT MECHANISMS MEDICAID APM LEGAL OPTIONS ALIGN WITH MEDICAID DELIVERY SYSTEMS REFORM INITIATIVES 28
29 SMART-D Website and Phase 1 Reports See Research and reports tab: 1. Summary Report 2. Legal Brief 3. Economic Analysis 4. APM Brief 5. MED Policy Report 29
30 SMART-D Technical Assistance Center s goal is to support states with technical assistance resources for development of APM implementation plans SMART-D team has identified technical assistance needs and opportunities in four areas: 1. Economic Analysis of High Cost Drugs 2. Legal and Compliance Framework 3. APM Development 4. Communication and Engagement 30
31 SMART-D Economic Analysis of High Cost Drugs Found 64 high-cost specialty drugs accounted for 32.6% of Medicaid drug reimbursement spending and 3.1% of overall Medicaid spending in drugs reimbursed at over $600 per prescription = $72m in annual Medicaid expenditure There are at least 110 additional drugs in the pipeline in the next two years that are likely to meet this same criteria and have a similar budget impact 31
32 Legal and Compliance Analysis Framework Understand the current federal and state legal framework for Medicaid prescription drug coverage and payment through the Medicaid Drug Rebate Program (MDRP) Explore potential APM options within and outside MDRP to drive the use of clinically valuable drugs and manage prescription drug costs Accommodate different state Medicaid delivery system models (feefor-service or managed care contracting) Support value-based payment approaches with pharmacies and other health care providers, in addition to agreements negotiated directly with prescription drug manufacturers Align with state Medicaid value-based payment and delivery system transformation efforts 32
33 State Opportunities: Pathways Pathway One: Pathway Two: Pathway Three: Pathway Four: Pathway Five: Pathway Six: Pathway Seven: Pathway Eight: Supplemental Rebate Arrangements Managed Care Organization (MCO) Contracting MCO/340B Covered Entity Partnerships Hospital Dispensed Covered Outpatient Drugs Physician Administered Drugs That Fall Outside Covered Outpatient Drug Definition Alternative Benefit Plan Section 1115 Waiver 340B with Innovative Care Delivery Models 33
34 State Medicaid Alternative Reimbursement and Purchasing Test for High Cost Drugs (SMART-D): Initial Experience Working with SMART-D States 34
35 Drugs & Conditions Prioritized for Potential APM Development Hemophilia Diabetes long acting insulin Anti coagulants Anti inflammatories Oral chemotherapy Atypical Antipsychotic Long Acting Injectables Multiple Sclerosis Cystic Fibrosis Orphan drugs (SMA) Hepatitis C
36 State Opportunities: Pathways Currently Under Exploration by SMART-D States? Pathway One: Pathway Two: Pathway Three: Pathway Four: Pathway Five: Pathway Six: Pathway Seven: Pathway Eight: Supplemental Rebate Arrangements Managed Care Organization (MCO) Contracting MCO/340B Covered Entity Partnerships Hospital Dispensed Covered Outpatient Drugs Physician Administered Drugs That Fall Outside Covered Outpatient Drug Definition Alternative Benefit Plan Section 1115 Waiver 340B with Innovative Care Delivery Models 36
37 SMART-D APM Characteristics To Date Alternative models that generate viable discussions have certain characteristics, such as: a) Good competition in drug class, with some branded drugs newer to market, and a contract outcome measure that can be easily tracked in claims data. b) Rare or orphan diseases where the Medicaid program can organize patient care into a center of excellence model including wrap-around patient care services to improve clinical outcomes, drug adherence, and data gathering for clinical outcome measures. c) Multi-state opportunities where a drug manufacturer needs scale and a certain number of lives to make an alternative model worthwhile for outcome measurement. 37
38 Overview of SMART-D APM Development Stage 1: Engage & Identify Draft APM strategy with state team Engage manufacturers and other key partners (340b, MCOs, CMS) Collect baseline data to support APM development Stage 2: Formalize & Finalize Finalize APM & secure state leadership support Finalize contracts between States, manufacturers, and other parties Establish evaluation plan & data collection methodology Stage 3: Implement & Monitor Implement APM Implement data tracking, monitoring, and reporting
39 Questions and Discussion 39
OHSU Center for Evidence-based Policy Rhonda Anderson, RPh Director of Pharmacy National Conference of State Legislators San Diego, CA December 10,
OHSU Center for Evidence-based Policy Rhonda Anderson, RPh Director of Pharmacy National Conference of State Legislators San Diego, CA December 10, 2017 Today s Presentation Center for Evidence-based Policy
More informationStates and the Rising Cost of Pharmaceuticals: A Call to Action
States and the Rising Cost of Pharmaceuticals: A Call to Action January 11, 2017 3:30-4:30 pm ET Call-in: (877) 717-9270 Working Group on Pharmaceutical Drug Costs Supported by Kaiser Permanente & The
More informationAppendix I: Data Sources and Analyses. Appendix II: Pharmacy Benefit Management Tools
Appendix I: Data Sources and Analyses This brief includes findings from analyses of the Centers for Medicare & Medicaid Services (CMS) State Drug Utilization Data 1 and CMS 64 reports for federal fiscal
More informationGlossary of Terms (Terms are listed in Alphabetical Order)
Glossary of Terms (Terms are listed in Alphabetical Order) Access Access refers to the availability and location of pharmacies that participate in the network that serves your pharmacy benefit plan. Acute
More informationA Payor and Provider s Perspective on Drug Pricing. Sharon Levine, MD Executive Vice President, The Permanente Federation
A Payor and Provider s Perspective on Drug Pricing Sharon Levine, MD Executive Vice President, The Permanente Federation National Academies of Sciences, Engineering and Medicine Stakeholder Meeting on
More informationCBI 4th Reimbursement and Contracting Conference: Key Challenges Related to Specialty Drug Pricing and Contracting
CBI 4th Reimbursement and Contracting Conference: Key Challenges Related to Specialty Drug Pricing and Contracting Avalere Health An Inovalon Company February 28, 2017 Growth in Drug Costs Relative to
More informationSteve Liles, PharmD Senior Director, Value Based Purchasing Magellan Medicaid Administration
Medicaid Drug Rebates Steve Liles, PharmD Senior Director, Value Based Purchasing Magellan Medicaid Administration Medicaid Drug Rebates History of Medicaid Drug Rebates and Preferred Drug Lists Affordable
More informationPRESCRIPTION DRUG SPENDING IN THE U.S. HEALTH CARE SYSTEM: AN ACTUARIAL PERSPECTIVE
PRESCRIPTION DRUG SPENDING IN THE U.S. HEALTH CARE SYSTEM: AN ACTUARIAL PERSPECTIVE Moderator Audrey Halvorson, Vice Chairperson, Health Practice Council Presenters Karen Bender, Member, Prescription Drug
More informationOverview of Coverage of Drugs Under the Medicaid Medical Benefit
Overview of Coverage of Drugs Under the Medicaid Medical Benefit June 4, 2008 Amanda Bartelme Avalere Health LLC Avalere Health LLC The intersection of business strategy and public policy Medical vs. Pharmacy
More informationFEEL BETTER. CONNECTED.
FEEL BETTER. CONNECTED. Connected across pharmacy and medical. To take you further. Katy Wong, RPh, MBA Vice President, Producer Relations Cigna Pharmacy Management Offered by: Cigna Health and Life Insurance
More informationDecember 15, 2017 (31 State SPAs)
New State SPAs Reimburse 340B Covered Entities at Actual Acquisition Cost: Creates Disincentives For 340B Entities to Choose the Lowest Cost Drugs December 15, 2017 (31 State SPAs) On January 21, 2016,
More informationuninsured The Role of Clinical and Cost Information in Medicaid Pharmacy Benefit Decisions: Experience in Seven States
kaiser commission on medicaid and the uninsured The Role of Clinical and Cost Information in Medicaid Pharmacy Benefit Decisions: Experience in Seven States Prepared by Jenny Gaffney, Marielle Kress, Caroline
More informationPharmacy Benefit Managers Overview
Pharmacy Benefit Managers Overview A Presentation to the House Health Innovation Subcommittee Mary Alice Nye, Ph.D. Health and Human Services Staff Director, OPPAGA December 6, 2017 Pharmacy Benefit Managers
More informationProvide sufficient incentive for providers to maximize health outcomes and value while reducing costs;
March 27, 2017 Francis J. Crosson, MD Chair Medicare Payment Advisory Commission 425 I Street, N.W., Suite 701 Washington, DC 20001 By Electronic Delivery Dear Chairman Crosson: On behalf of the American
More informationMedicare Part D: Better understanding the nuances of the prescription drug benefit
Medicare Part D: Better understanding the nuances of the prescription drug benefit Rajul A. Patel, Pharm.D, Ph.D. TJL School of Pharmacy & Health Sciences University of the Pacific July 26 th, 2018 Today
More informationJim Frizzera, Principal Health Management Associates
Jim Frizzera, Principal Health Management Associates Established the Medicaid disproportionate share hospital (DSH) adjustment. Required States to set Medicaid reimbursement rates for hospital inpatient
More information2016 Drug Trend Report Executive Summary
COMMERCIAL 2016 Drug Trend Report Executive Summary EXPRESS SCRIPTS 2016 DRUG TREND REPORT COMMERCIAL EXECUTIVE SUMMARY 1 Driving undeniable value for plans and patients in 2016 The issue of rising drug
More informationMedicaid in a Time of Historic Change: Prescription Drugs and Costs A Medicaid Perspective
Medicaid in a Time of Historic Change: Prescription Drugs and Costs A Medicaid Perspective Presented to NCSL Legislative Summit August 9, 2016 Steve Fitton, Principal at Health Management Associates rev
More informationTexas Vendor Drug Program. Drug Addition Process. Effective Date. December 2017
Texas Vendor Drug Program Drug Addition Process Effective Date December 2017 This is a working document to provide a resource to interested internal and external stakeholders. Questions or comments regarding
More informationThe Management of Specialty Drugs: Opportunities and Challenges
The Management of Specialty Drugs: Opportunities and Challenges Scott Woods Senior Director, Policy PCMA Innovations X April 5, 2016 Specialty Drugs to be Half of Spend by 2018 Forecast PMPM Net Drug
More informationInsurance & Medication Access
Insurance & Medication Access Ontario Rheumatology Association 12th Annual Meeting JW Marriott The Rosseau Muskoka May 25, 2013 Suzanne Lepage, Private Health Plan Strategist Learning Objectives Understand
More informationACTIVELY MANAGED DRUG SOLUTIONS SPECIALTY DRUGS. Supporting employees and building sustainable drug plans...together
ACTIVELY MANAGED DRUG SOLUTIONS SPECIALTY DRUGS Supporting employees and building sustainable drug plans...together Not available in the province of Quebec INTRODUCING THE SPECIALTY DRUG PROGRAM If you
More informationHow the Federal Government Can Help States Address Rising Prescription Drug Costs
A PUBLICATION OF THE NATIONAL ACADEMY FOR STATE HEALTH POLICY February 2018 How the Federal Government Can Help States Address Rising Prescription Drug Costs Supported by The Commonwealth Fund Introduction
More informationPhRMA Perspective: Government Policies to Support Innovative Contracting Approaches
PhRMA Perspective: Government Policies to Support Innovative Contracting Approaches CBI s PAP 2017 Michelle Drozd, Deputy Vice President Policy & Research Department October 12, 2016 Agenda Recent trends
More informationSavings Generated by New York s Medicaid Pharmacy Reform
Savings Generated by New York s Medicaid Pharmacy Reform Sponsored by: Pharmaceutical Care Management Association Prepared by: Special Needs Consulting Services, Inc. October 2012 Table of Contents I.
More informationManaging Specialty Pharmaceuticals: Balancing Access and Affordability
Managing Specialty Pharmaceuticals: Balancing Access and Affordability Commercial Health Plan Perspective The Health Industry Forum July 16, 2008 Presented by: Margaret M. (Peggy) Johnson, R.Ph. Vice President
More informationChallenges in High Dollar Drugs. Suzanne Francart, PharmD, BCPS Manager Infusion Services & Medication Assistance Program UNC HealthCare
Challenges in High Dollar Drugs Suzanne Francart, PharmD, BCPS Manager Infusion Services & Medication Assistance Program UNC HealthCare Disclosure I have no relevant conflicts of interest to disclose Learning
More informationNew York Institutes New Medicaid Drug Price Control Measures. State Budget Includes Medicaid Drug Expenditure Cap. FDA & Life Sciences Practice Group
FDA & Life Sciences Practice Group April 21, 2017 For more information, contact: John D. Shakow +1 202 626 5523 jshakow@kslaw.com Brian A. Bohnenkamp +1 202 626 5413 bbohnenkamp@kslaw.com Elizabeth F.
More informationUnsupported Price Increase Assessment
Unsupported Price Increase Assessment Draft Protocol January 17, 2019 Institute for Clinical and Economic Review Institute for Clinical and Economic Review, 2019 Table of Contents 1. Background... 1 2.
More informationPharmaceuticals: Can or Should We Do Anything About Rising Drug Costs? Caroline F. Pearson
Pharmaceuticals: Can or Should We Do Anything About Rising Drug Costs? Caroline F. Pearson Avalere Health An Inovalon Company April 2015 Number of News Articles Public Focus on Drug Prices Increased Dramatically
More informationRe: Medicare Prescription Drug Benefit Manual Draft Chapter 6
September 26, 2006 BY ELECTRONIC DELIVERY Cynthia Tudor, Ph.D. Director, Medicare Drug Benefit Group Centers for Medicare & Medicaid Services Mail Stop C4-13-01 7500 Security Boulevard Baltimore, MD 21244
More informationPotential Federal and State-by-State Savings if Medicaid Pharmacy Programs were Optimally Managed
Potential Federal and State-by-State Savings if Medicaid Pharmacy Programs were Optimally Managed February 2011 Commissioned by the Pharmaceutical Care Management Association Prepared by: Joel Menges Shirley
More informationTable 15 Premium, Enrollment Fee, and Cost Sharing Requirements for Children, January 2017
State Required in Medicaid Required in CHIP (Total = 36) 1 Lowest Income at Which Premiums Begin (Percent of the FPL) 2 Required in Medicaid Required in CHIP (Total = 36) 1 Lowest Income at Which Cost
More informationCRS Report for Congress
Order Code RS21071 Updated February 15, 2005 CRS Report for Congress Received through the CRS Web Medicaid Expenditures, FY2002 and FY2003 Summary Karen L. Tritz Analyst in Social Legislation Domestic
More informationMedicaid Prescribed Drug Program Spending Control Initiatives. For the Quarter April 1, 2014 through June 30, 2014
Medicaid Prescribed Drug Program Spending Control Initiatives For the Quarter April 1, 2014 through June 30, 2014 Report to the Florida Legislature January 2015 Table of Contents Purpose of Report... 1
More informationInsights into pharmacy benefit management, drug trend and the future
Insights into pharmacy benefit management, drug trend and the future 1 Where does your health care dollar go? 2 Pharmacy share of total health spend 25% 21% 20% 19% 15% 10% 10% 5% 0% Retail Drugs as a
More informationPrescription Drugs (Rx) Fast Facts
HEALTH SEMINAR FOR NEWER LEGISLATORS Prescription Drugs Session Sunday April 15, 2018 Richard Cauchi, Program Director, NCSL Health Program Prescription Drugs (Rx) Fast Facts More than half of all Americans
More informationApril 8, Dear Mr. Levinson,
April 8, 2019 Daniel Levinson Office of Inspector General Department for Health and Human Services Cohen Building, Room 5527 330 Independence Ave, SW Washington, DC 20201 Re: Fraud and Abuse; Removal of
More informationUpdate. The authors of this article are all consultants with Huron Consulting Group, which serves the continuum of life sciences organizations
Life Science Compliance Update REPRINTED FROM U.S. EDITION Volume 2.1 February 2016 Your Special Relationships Specialty Pharmacies and 5 Thoughtful Controls to Consider public advocates, and the media
More informationLindsey Imada, PharmD Candidate 2016 Midwestern University, Chicago College of Pharmacy
Lindsey Imada, PharmD Candidate 2016 Midwestern University, Chicago College of Pharmacy Under the Preceptorship of Dr. Craig Stern Pro Pharma Pharmaceutical Consultants, Inc. September 11, 2015 S OBJECTIVES
More informationEstimate of Medicare Part D Costs After Accounting for Manufacturer Rebates
October 2016 Estimate of Medicare Part D Costs After Accounting for Manufacturer Rebates A Study of Original Branded Products in the U.S. $ Introduction The cost of medicines in the U.S. has been the subject
More informationThe U.S. Healthcare System: How Pharmacy Benefit Managers Impact Prescription Drug Use. Presented by Daniel Tomaszewski Pharmd, PhD
The U.S. Healthcare System: How Pharmacy Benefit Managers Impact Prescription Drug Use Presented by Daniel Tomaszewski Pharmd, PhD 1 Medical Vs. Pharmacy Coverage Medical Insurance Managed by an Insurance
More informationKEEPING PRESCRIPTION DRUGS AFFORDABLE: The Value of Pharmacy Benefit Managers (PBMs)
The Texas Association of Health Plans Representing health insurers, health maintenance organizations, and other related health care entities operating in Texas. KEEPING PRESCRIPTION DRUGS AFFORDABLE: The
More informationPrescription Medicines: Costs in Context. Updated August 2016
Prescription Medicines: Costs in Context Updated August 2016 Medicines are Transforming the Treatment OF DEVASTATING DISEASES HEPATITIS C The leading cause of liver transplants and the reason liver cancer
More informationManatt on Medicaid: Evolving Trends in the Pharmaceutical Benefit and the Role of Medicaid Managed Care. October 17, 2018
Manatt on Medicaid: Evolving Trends in the Pharmaceutical Benefit and the Role of Medicaid Managed Care October 17, 2018 Introduction 1 Anthony J. Fiori Sandy W. Robinson Alex Dworkowitz Agenda 2 Medicaid
More information2014 SUMMARY OF BENEFITS
2014 SUMMARY OF BENEFITS First Health Part D Value Plus (PDP) Prescription Drug Plan S5569, S5768 Y0022_PDP_2014_S5569_S5768_SB accepted SECTION I INTRODUCTION TO SUMMARY OF BENEFITS Thank you for your
More informationAccount-based medical plans Summary of Benefits and Coverage supplement
Account-based medical plans Summary of Benefits and Coverage supplement We want you to have tools and resources to help you make informed health care decisions. For each of the medical plans this year,
More informationWikiLeaks Document Release
WikiLeaks Document Release February 2, 2009 Congressional Research Service Report RS21071 Medicaid Expenditures, FY2003 and FY2004 Karen Tritz, Domestic Social Policy Division January 17, 2006 Abstract.
More informationPrescription Cost Control: State Options. } January 24, 2017 } Annapolis, MD } Ellen Andrews, PhD } } CSG/ERC
Prescription Cost Control: State Options } January 24, 2017 } Annapolis, MD } Ellen Andrews, PhD } eandrews@csg.org } CSG/ERC The problem } In 2015 US prescription drug spending grew faster than any other
More informationUnderstanding Pharmacy Benefit Management Services
Understanding Pharmacy Benefit Management Services Peter Cullen VP, Business Development and Strategic Initiatives March 12, 2014 Innovation Session Overview and Learning Objectives Session Overview: Provide
More informationManufacturer Patient Support Initiatives: Current Practices and Recent Challenges. Andrew Ruskin Morgan Lewis
Intersecting Worlds of Drug, Device, Biologics and Health Law AHLA/FDLI May 22, 2012 Manufacturer Patient Support Initiatives: Current Practices and Recent Challenges by Andrew Ruskin Morgan Lewis The
More informationMedicare Congress: Fee for Service Trends: A Look at Medicare Part B
Medicare Congress: Fee for Service Trends: A Look at Medicare Part B November 1, 2005 Lauren Geyer Barnes Avalere Health LLC Avalere Health LLC The intersection of business strategy and public policy Three
More informationBlue Essentials, Blue Advantage HMO SM and Blue Premier SM Provider Manual - Pharmacy
Blue Essentials, Blue Advantage HMO SM and Blue Premier SM Provider Manual - In this Section there are references unique to Blue Essentials, Blue Advantage HMO and Blue Premier. These network specific
More informationMedicaid Prescribed Drug Program. Spending Control Initiatives
Medicaid Prescribed Drug Program Spending Control Initiatives For Quarters Ended September 30, December 31, Table of Contents Purpose of Report... 1 Executive Summary... 2 Pharmacy Appropriations and Spending
More information2.05 Predictive Modeling P4P and Physician Engagement. Pay for Performance Summit February 7, 2006
2.05 Predictive Modeling P4P and Physician Engagement Pay for Performance Summit February 7, 2006 1 Agenda Three Key Healthcare Trends About Predictive Modeling About Reporting Business and Clinical Outcomes
More informationInnovative Strategies for Managing the Rising Cost of Specialty Drugs
Innovative Strategies for Managing the Rising Cost of Specialty Drugs Mid-sized Retirement and Healthcare Plan Management Conference Chicago, IL June 5, 2013 Managing the Rising Cost of Specialty Drugs
More informationProposed MAC Legislation May Increase Costs Of Affected Generic Drugs By More Than 50 Percent. Prepared for
Proposed MAC Legislation May Increase Costs Of Affected Generic Drugs By More Than 50 Percent Prepared for April 2014 Executive Summary MAC (Maximum Allowable Cost) is a savings tool used by Medicare,
More informationImpact of Medicaid MCO Claims on Forecasts and Accruals
Impact of Medicaid MCO Claims on Forecasts and Accruals 19 th Annual CBI Medicaid and Government Pricing Congress Tuesday, May 9, 2017 Partha Chatterjee Managing Partner pchatterjee@akaragroup.com (973)
More informationMemberChoice FORMULARY MANAGEMENT MEDICATION THERAPY MANAGEMENT (MTM) SPECIALTY DRUG MANAGEMENT. Specialty Drug Management
MemberChoice FORMULARY MANAGEMENT MEDICATION THERAPY MANAGEMENT (MTM) SPECIALTY DRUG MANAGEMENT SPECIALTY DRUG MANAGEMENT 1 1% Prescriptions Written in 2012 99% 25% Prescription Drug Spending in 2012 75%
More informationMedicaid Managed Care 101: Building a Common Understanding for the Healthy Students, Promising Futures Learning Collaborative
Medicaid Managed Care 101: Building a Common Understanding for the Healthy Students, Promising Futures Learning Collaborative March 30, 2017 Lena O Rourke, on behalf of Healthy Schools Campaign Ashley
More informationRe: Medicare Prescription Drug Benefit Manual Draft Chapter 5
September 18, 2006 BY ELECTRONIC DELIVERY Cynthia Tudor, Ph.D. Director, Medicare Drug Benefit Group Centers for Medicare and Medicaid Services Department of Health and Human Services Mail Stop C4-13-01
More informationFormulary Access for Patients with Mental Health Conditions
Formulary Access for Patients with Mental Health Conditions Background on Avalere s PlanScape and Methodology for Formulary Analysis PlanScape Methodology This analysis reviews formulary coverage in the
More informationECONOMIC PRINCIPLES IMPACTING MANAGED CARE PHARMACY. Adrian Washington PharmD., MBA Vice President of Client Management United Healthcare OptumRx
ECONOMIC PRINCIPLES IMPACTING MANAGED CARE PHARMACY Adrian Washington PharmD., MBA Vice President of Client Management United Healthcare OptumRx As vice president, Adrian is responsible for strategic planning
More informationThe Honorable Alex Azar Secretary US Department of Health and Human Services 200 Independence Avenue SW Washington, DC 20201
July 13, 2018 The Honorable Alex Azar Secretary US Department of Health and Human Services 200 Independence Avenue SW Washington, DC 20201 Secretary Azar, The American Academy of Neurology (AAN) is the
More informationProposed MAC Legislation May Increase Costs of Affected Generic Drugs By More Than 50 Percent. Prepared for
Proposed MAC Legislation May Increase Costs of Affected Generic Drugs By More Than 50 Percent Prepared for January 2015 Executive Summary MAC (Maximum Allowable Cost) is a savings tool used by Medicare,
More informationPharmacy Benefit Management in Oncology
Pharmacy Benefit Management in Oncology October 28 th, 2015 Business Health Care Group Protecting the Future of Oncology Care: A Community Conversation Brent Eberle RPh MBA Chief Pharmacy Officer, Navitus
More informationLITIGATING AWP. Mitch Lazris/Lyndon Tretter Hogan & Hartson L.L.P. November 15, 2002
LITIGATING AWP Mitch Lazris/Lyndon Tretter Hogan & Hartson L.L.P. November 15, 2002 Litigation Landscape Federal Gov t/states/private Class Actions Payment Systems Medicare (based on 95% of AWP) Medicare
More informationMarch 4, Dear Senator Wyden and Senator Grassley,
March 4, 2016 The Honorable Ron Wyden Ranking Member Committee on Finance United States Senate The Honorable Charles Grassley Member Committee on Finance United States Senate Dear Senator Wyden and Senator
More informationThe Cost of Specialty Drugs: Payer Perspectives
ADVISORY REPORT AM PL E PA G ES S A S G ES A FirstWord Dossier Advisory report Published Copyright 2016 Doctor s Guide Publishing Limited Part of the FirstWord Dossier family of reports exploring important
More informationTable of Contents. I. Executive Summary and Introduction..2 A. Overview.2 B. Key Findings...2 C. Summary of Approach...5
Table of Contents I. Executive Summary and Introduction..2 A. Overview.2 B. Key Findings...2 C. Summary of Approach......5 II. III. Detailed Data Analyses Findings...6 A. Louisiana Rankings on Key Metrics....6
More informationMarc Claussen, Chiesi USA, Director, Market Access. Donna White, Chiesi USA, Sr. Director, Contracting and Compliance
Marc Claussen, Chiesi USA, Director, Market Access Donna White, Chiesi USA, Sr. Director, Contracting and Compliance The views/observations expressed in this presentation are the personal views/observations
More information2008 Medicare Part D: Pharmacist's Survival Guide. Ronnie DePue, R.Ph., CGP
2008 Medicare Part D: Pharmacist's Survival Guide Ronnie DePue, R.Ph., CGP Objectives At the completion of this program, the participant will be able to: 1. Give an overview of the Medicare Prescription
More informationReleased: March 8, Comments Due: May 9, 2016
SUMMARY AMCP Summary: Medicare Program; Part B Drug Payment Model Released: March 8, 2016 Comments Due: May 9, 2016 On March 8, 2016, the Centers for Medicare and Medicaid Services (CMS) released a proposed
More informationChapter 21. Pharmacy Services
Last Updated: 11/14/2018 1:52:00 PM Chapter 21 Pharmacy Services Definitions Compounded Prescription: A prescription prepared in accordance with Minnesota Rules 6800.3100. Dispensing Date: The actual date
More informationStanding strong for payers and patients
Standing strong for payers and patients Eric Slusser, EVP, Chief Financial Officer Everett Neville, SVP Supply Chain and Specialty B A N K O F A M E R I C A M E R R I L L L Y N C H H E A LTH C A RE CONFERENCE
More informationThird Quarter 2017 Earnings Conference Call
Third Quarter 2017 Earnings Conference Call Larry Merlo President & Chief Executive Officer Dave Denton Executive Vice President & Chief Financial Officer November 6, 2017 Forward-looking Statements This
More informationMedicaid and CHIP Eligibility, Enrollment, Renewal, and Cost-Sharing Policies as of January
State Required in Medicaid Table 15 Premium, Enrollment Fee, and Cost-Sharing Requirements for Children January 2016 Premiums/Enrollment Fees Required in CHIP (Total = 36) Lowest Income at Which Premiums
More informationCMS Grant Programs: Improving Access & Quality for Medicaid Beneficiaries and the Uninsured
CMS Grant Programs: Improving Access & Quality for Medicaid Beneficiaries and the Uninsured Jessica Pollak Kahn, MPH Centers for Medicare & Medicaid Services Presentation Objectives Medicaid Transformation
More informationFigure 1. Medicaid Status of Medicare Beneficiaries, Partial Dual Eligibles (1.0 Million) 3% 15% 83% Medicare Beneficiaries = 38.
I S S U E P A P E R kaiser commission on medicaid and the uninsured September 2003 A Prescription Drug Benefit in Medicare: Implications for Medicaid and Low- Income Medicare Beneficiaries A prescription
More informationBERKELEY RESEARCH GROUP. Executive Summary
Executive Summary Within the U.S. healthcare system, the flow of dollars in the pharmaceutical marketplace is a complex process involving a variety of stakeholders and myriad rebates, discounts, and fees
More informationWelcome. AMCP Partnership Forum. Designing Benefits and Payment Models for Innovative High Investment Medications
AMCP Partnership Forum Designing Benefits and Payment Models for Innovative High Investment Medications Welcome Bri Palowitch, PharmD, BCGP Manager, Pharmacy Affairs Academy of Managed Care Pharmacy Disclaimer
More informationCWAG Prescription Drug Pricing Webinar
CWAG Prescription Drug Pricing Webinar January 9, 2018 Kipp Snider, J.D. Vice President, State Policy Pharmaceutical Research & Manufacturers of America (PhRMA) Medicines Are Expected to Account for a
More informationModernizing Louisiana s Medicaid
Modernizing Louisiana s Medicaid Pharmacy Program Prescription for Reform F i n a l R e f o r m C o n c e p t August 24, 2012 Modernizing Louisiana s Medicaid Pharmacy Program Our Vision: Principles for
More informationRe: Department of Health and Human Services: Promoting Healthcare Choice and Competition Across the United States
Assistant Secretary for Planning and Evaluation Room 415F U.S. Department of Health and Human Services 200 Independence Avenue, SW Washington, D.C. 20201 Submitted via email CompetitionRFI@hhs.gov Re:
More information340B Program Update & Recommendations for Monitoring Program Compliance October
340B Program Update & Recommendations for Monitoring Program Compliance October 2 2014 Speaker Biography Ray Albertina Director Deloitte & Touche LLP +1 (314) 342 4984 ralbertina@deloitte.com Ray is a
More informationPharmaceutical Management Commercial Plans
Pharmaceutical Management Commercial Plans 2015 Toll Free Contact Number: (888) 327-0671 Medical Management: (810) 733-9711 Visit our website at: MclarenHealthPlan.org Introduction Pharmaceutical Management
More informationAugust 11, Submitted electronically via Regulations.gov
August 11, 2017 Submitted electronically via Regulations.gov Centers for Medicare & Medicaid Services Department of Health and Human Services Attention: CMS-1678-P PO Box 8013 Baltimore, MD 21244-1850
More informationHow Does CCNC s Model Align with Value Based Payments? Lead Community Pharmacy Coordinator CCNC V.P. Moose Pharmacy Joe Moose, PharmD
Improving care through shared knowledge How Does CCNC s Model Align with Value Based Payments? Lead Community Pharmacy Coordinator CCNC V.P. Moose Pharmacy Joe Moose, PharmD $100 Total Healthcare Spend
More informationNational Drug Code (NDC) Requirement Policy, Facility and Professional
National Drug Code (NDC) Requirement Policy, Facility and Professional IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY You are responsible for submission of accurate claims. This reimbursement policy is
More informationHow is the Affordable Care Act Leading to Changes in Medicaid Today? State Adoption of Five New Options
P O L I C Y B R I E F kaiser commission on medicaid and the uninsured How is the Affordable Care Act Leading to Changes in Medicaid Today? State Adoption of Five New Options May 2012 One primary goal of
More informationHow 14 States Have Designed Pharmacy Assistance Programs
How 14 States Have Designed Pharmacy Assistance Programs by John Hansen T his chapter overviews programs in 14 states which were providing prescription drug benefits for 760,000 elderly and other low-income
More informationThe 340B drug discount program was created in 1992
Proposed Rule Changes for 340B Programs: Overview and Impact Anthony Zappa, PharmD, MBA Specialty Healthcare Benefits Council The 340B drug discount program was created in 1992 as a means for certain nonprofit
More informationTHE COST OF NOT EXPANDING MEDICAID
REPORT THE COST OF NOT EXPANDING MEDICAID July 2013 PREPARED BY John Holahan, Matthew Buettgens, and Stan Dorn The Urban Institute The Kaiser Commission on Medicaid and the Uninsured provides information
More informationuninsured Medicaid Today; Preparing for Tomorrow A Look at State Medicaid Program Spending, Enrollment and Policy Trends
kaiser commission on medicaid and the uninsured Medicaid Today; Preparing for Tomorrow A Look at State Medicaid Program Spending, Enrollment and Policy Trends Results from a 50-State Medicaid Budget Survey
More informationCody Wiberg, Pharm.D., M.S., R.Ph. Executive Director Minnesota Board of Pharmacy
Cody Wiberg, Pharm.D., M.S., R.Ph. Executive Director Minnesota Board of Pharmacy UNITED STATES MILITARY CANADIAN MILITARY Pharmacy Preferred Providers as Selected by Drug Manufacturers and Third
More informationData Note: What if Per Enrollee Medicaid Spending Growth Had Been Limited to CPI-M from ?
Data Note: What if Per Enrollee Medicaid Spending Growth Had Been Limited to CPI-M from 2001-2011? Rachel Garfield, Robin Rudowitz, and Katherine Young Congress is currently debating the American Health
More informationAPPENDIX B: VENDOR DRUG PROGRAM TEXAS MEDICAID PROVIDER PROCEDURES MANUAL: VOL. 1
APPENDIX B: VENDOR DRUG PROGRAM TEXAS MEDICAID PROVIDER PROCEDURES MANUAL: VOL. 1 APRIL 2018 TEXAS MEDICAID PROVIDER PROCEDURES MANUAL: VOL. 1 APRIL 2018 APPENDIX B: VENDOR DRUG PROGRAM Table of Contents
More informationFourth Quarter 2018 Earnings Conference Call
Fourth Quarter 2018 Earnings Conference Call Larry Merlo President & Chief Executive Officer Eva Boratto Executive Vice President & Chief Financial Officer February 20, 2019 Cautionary Statement Regarding
More informationStatus of CHIP Prospective Payer System Implementation: An Assessment of State CHIP Directors
The traditional provider cost-based reimbursement system for federally-qualified health centers (FQHCs) was replaced with a new prospective payment system (PPS) under The Medicare, Medicaid and SCHIP Benefits
More informationPharmaceutical Management Community Plans 2018
Pharmaceutical Management Community Plans 2018 Customer Service: (888) 327-0671 TTY: 711 Pharmacy Administration: (810) 244-1660 Introduction Pharmaceutical management promotes the use of the most clinically
More information